Lukas Pavelka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lukas Pavelka has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Rejko Krüger
Luxembourg Institute of Health
13 shared publications - Enrico Glaab
Biomedical Data Science Group, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg
7 shared publications - Armin Rauschenberger
Biomedical Data Science, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
5 shared publications - Patrick May
Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
4 shared publications - Sinthuja Pachchek
LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Sur-Alzette, Luxembourg
3 shared publications - Christine Klein
University of Luebeck
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Wiley in Movement Disorders Clinical Practice
Disease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial
Background: Freezing of gait (FoG) belongs to most pressing unmet symptoms in the treatment of Parkinson's disease. Objectives: To explore whether combined subthalamic and nigral (STN + SNr) deep brain stimulation improves FoG compared with optimized STN stimulation alone; to identify clinical variables associated with therapeutic response. Methods: In this exploratory multicenter randomized controlled double‐blind trial, we recruited patients from our existing cohorts and randomized them 1:1 to STN or STN + SNr . After baseline, patients were followed with close interim visits (visits 1–5) for 90 days (visit 6). The Freezing of Gait Assessment Course ( FoG ‐ AC ) was the primary endpoint and was evaluated at P < 0.2 with exploratory intent. Secondary endpoints assessed responder rates, treatment dynamics, predictors of response, and patient preferences. Results: At V6, STN (n = 23) and STN + SNr (n = 22) FoG‐AC outcomes did not differ significantly. We identified responders with clinically meaningful FoG improvement in both the STN (n = 7) and STN + SNr (n = 8) groups. In STN + SNr responders, mean disease duration was ~12 years, which was ~4.5 years shorter than in non‐responders, but there were no differences in motor and cognitive functions. Treatment dynamics suggested that FoG responders improved slowly and gradually. The STN + SNr responder group showed numerically stronger FoG improvement compared with STN responders. Additionally, 15 STN compared to 10 STN + SNr patients wished to change treatment after the RCT phase and before unblinding. Both STN and STN + SNr treatment was safe. Conclusions: Future trials evaluating adjunctive STN + SNr stimulation should stratify patients by disease duration to optimize outcomes.
- 12 October 2026
- Published by Wiley in Movement Disorders Clinical Practice
Open AccessDisease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial
Background: Freezing of gait (FoG) belongs to most pressing unmet symptoms in the treatment of Parkinson's disease. Objectives: To explore whether combined subthalamic and nigral (STN + SNr) deep brain stimulation improves FoG compared with optimized STN stimulation alone; to identify clinical variables associated with therapeutic response. Methods: In this exploratory multicenter randomized controlled double‐blind trial, we recruited patients from our existing cohorts and randomized them 1:1 to STN or STN + SNr . After baseline, patients were followed with close interim visits (visits 1–5) for 90 days (visit 6). The Freezing of Gait Assessment Course ( FoG ‐ AC ) was the primary endpoint and was evaluated at P < 0.2 with exploratory intent. Secondary endpoints assessed responder rates, treatment dynamics, predictors of response, and patient preferences. Results: At V6, STN (n = 23) and STN + SNr (n = 22) FoG‐AC outcomes did not differ significantly. We identified responders with clinically meaningful FoG improvement in both the STN (n = 7) and STN + SNr (n = 8) groups. In STN + SNr responders, mean disease duration was ~12 years, which was ~4.5 years shorter than in non‐responders, but there were no differences in motor and cognitive functions. Treatment dynamics suggested that FoG responders improved slowly and gradually. The STN + SNr responder group showed numerically stronger FoG improvement compared with STN responders. Additionally, 15 STN compared to 10 STN + SNr patients wished to change treatment after the RCT phase and before unblinding. Both STN and STN + SNr treatment was safe. Conclusions: Future trials evaluating adjunctive STN + SNr stimulation should stratify patients by disease duration to optimize outcomes.
- Open Access
- 11 March 2026
- Published by Elsevier in SSRN Electronic Journal
A Precision Medicine Model Estimating Off-Medication Motor State in Parkinson`s Disease
Background: On-medication motor assessment in Parkinson's Disease confounds treatment response with the disease's motor state. To properly quantify an off-medication state, we predicted the patient's underlying motor severity and characterized their response to treatment through individualized trajectories without relying on medication washout.Methods: A retrospective, longitudinal analysis was conducted on participants enrolled in the Parkinson's Progression Markers Initiative. We developed and internally validated a linear mixed-effects model using a subject-wise nested cross-validation framework. The primary outcome was MDS-UPDRS III in the off-medication state, approximated by levodopa equivalent daily dose, disease duration, presence of dyskinesia, and MDS-UPDRS III while on medication, as primary predictors. Principal component analysis was applied to model residuals to characterize treatment response patterns across off-medication predictions.Findings: The model predicted off-medication MDS-UPDRS III within a 4-point margin. Up to 12% of observations exhibit a limited treatment response, indicating potential under-recognized treatment resistance or dosage ceiling effects. In support of the treatment response patterns, principal component analysis uncovered clinically relevant differences between patterns, including statistically significant MDS-UPDRS III subitems, activities of daily living, and affective state scores between limited and excessive treatment response profiles. Thereby supporting the clinical utility in providing an individualized method of characterizing treatment response.Interpretation: By quantifying the underlying disease severity in the off-medication state, we can enhance the characterization of treatment efficacy and support improved treatment decisions in conventional clinical practice. This capability enables the detection of limited treatment responses and highlights potential underrecognized effects in individuals with more severe diseases, which can lead to undertreatment or dosage limitations. Furthermore, assessing medication response is achievable using routinely collected clinical measures.
- 11 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Precision Medicine Model Estimating Off-Medication Motor State in Parkinson`s Disease
Background: On-medication motor assessment in Parkinson's Disease confounds treatment response with the disease's motor state. To properly quantify an off-medication state, we predicted the patient's underlying motor severity and characterized their response to treatment through individualized trajectories without relying on medication washout.Methods: A retrospective, longitudinal analysis was conducted on participants enrolled in the Parkinson's Progression Markers Initiative. We developed and internally validated a linear mixed-effects model using a subject-wise nested cross-validation framework. The primary outcome was MDS-UPDRS III in the off-medication state, approximated by levodopa equivalent daily dose, disease duration, presence of dyskinesia, and MDS-UPDRS III while on medication, as primary predictors. Principal component analysis was applied to model residuals to characterize treatment response patterns across off-medication predictions.Findings: The model predicted off-medication MDS-UPDRS III within a 4-point margin. Up to 12% of observations exhibit a limited treatment response, indicating potential under-recognized treatment resistance or dosage ceiling effects. In support of the treatment response patterns, principal component analysis uncovered clinically relevant differences between patterns, including statistically significant MDS-UPDRS III subitems, activities of daily living, and affective state scores between limited and excessive treatment response profiles. Thereby supporting the clinical utility in providing an individualized method of characterizing treatment response.Interpretation: By quantifying the underlying disease severity in the off-medication state, we can enhance the characterization of treatment efficacy and support improved treatment decisions in conventional clinical practice. This capability enables the detection of limited treatment responses and highlights potential underrecognized effects in individuals with more severe diseases, which can lead to undertreatment or dosage limitations. Furthermore, assessing medication response is achievable using routinely collected clinical measures.
- Open Access
Sex-specific microRNA regulators of Parkinson’s disease: insights from cohort-stratified simulations of compensatory pathway dynamics
Parkinson’s disease (PD) exhibits sex differences in prevalence, symptom severity, and progression, suggesting distinct underlying molecular mechanisms. However, the pathophysiological mechanisms remain largely obscure, particularly in the context of the post-transcriptional regulations, where microRNAs (miRNAs) suppress the expression of multiple genes. Bulk transcriptomic data often blur these effects, especially when regulatory patterns vary by sex or cell type. miRNAs have emerged as key regulators of PD-related processes, but their complexity demands computational methods that enable capturing the functional impact at the pathway level. In this study, we investigated how sex may affect miRNA-regulated PD pathways using Boolean modeling across two large PD cohorts, the Parkinson’s Progression Markers Initiative (PPMI) and the Luxembourg Parkinson’s Study (LuxPark). First, differential expression analysis identified significant variations in miRNA expression between the sexes across both cohorts. These miRNAs were analysed to identify molecular pathways that are over-represented among the predicted targets of the dysregulated microRNAs (i.e. enrichment analysis). The enriched pathways were used to build Boolean models to simulate the effects of sex-specific miRNA dysregulation. These simulations showed consistent male-specific impairment in mitochondrial biogenesis, and respiratory chain activity. Mitophagy and oxidative stress response pathways were also disrupted, alongside dysregulation of autophagy-related protein-folding mechanisms. Our findings suggest that sex-specific miRNA dysregulation contributes to differences in molecular patterns in PD by influencing compensatory related pathways and responses. These results highlight the need for sex-stratified approaches in modeling, translational research, and precision medicine strategies for disease-modifying treatments.
Open AccessSex-specific microRNA regulators of Parkinson’s disease: insights from cohort-stratified simulations of compensatory pathway dynamics
Parkinson’s disease (PD) exhibits sex differences in prevalence, symptom severity, and progression, suggesting distinct underlying molecular mechanisms. However, the pathophysiological mechanisms remain largely obscure, particularly in the context of the post-transcriptional regulations, where microRNAs (miRNAs) suppress the expression of multiple genes. Bulk transcriptomic data often blur these effects, especially when regulatory patterns vary by sex or cell type. miRNAs have emerged as key regulators of PD-related processes, but their complexity demands computational methods that enable capturing the functional impact at the pathway level. In this study, we investigated how sex may affect miRNA-regulated PD pathways using Boolean modeling across two large PD cohorts, the Parkinson’s Progression Markers Initiative (PPMI) and the Luxembourg Parkinson’s Study (LuxPark). First, differential expression analysis identified significant variations in miRNA expression between the sexes across both cohorts. These miRNAs were analysed to identify molecular pathways that are over-represented among the predicted targets of the dysregulated microRNAs (i.e. enrichment analysis). The enriched pathways were used to build Boolean models to simulate the effects of sex-specific miRNA dysregulation. These simulations showed consistent male-specific impairment in mitochondrial biogenesis, and respiratory chain activity. Mitophagy and oxidative stress response pathways were also disrupted, alongside dysregulation of autophagy-related protein-folding mechanisms. Our findings suggest that sex-specific miRNA dysregulation contributes to differences in molecular patterns in PD by influencing compensatory related pathways and responses. These results highlight the need for sex-stratified approaches in modeling, translational research, and precision medicine strategies for disease-modifying treatments.
- Open Access
Rare but Relevant: Assessing Variants in Dystonia-linked Genes in Parkinson’s Disease
Background: Dystonia and Parkinson’s disease (PD) show clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective: To assess the frequency of dystonia-linked pathogenic variants in PD. Methods: We screened sequencing data from 15,738 individuals (7,851 PD, 4,287 atypical parkinsonism, and 3,600 unaffected) from GP2 and AMP-PD for variants in genes linked to isolated dystonia, dystonia-parkinsonism, and myoclonus-dystonia. Results: Pathogenic variants were only identified in PD patients. Forty-five PD individuals (0.57%) carried 26 distinct (likely) pathogenic variants in nine dystonia-linked genes, most frequently in GCH1 , followed by VPS16 . Conclusion: Though rare, pathogenic variants in dystonia-linked genes are present in clinically and pathologically diagnosed PD. Our results reinforce GCH1 as a PD-relevant gene with clinical implications, while variants identified in other genes are rare and of sometimes uncertain relation to the PD phenotype.
Open AccessRare but Relevant: Assessing Variants in Dystonia-linked Genes in Parkinson’s Disease
Background: Dystonia and Parkinson’s disease (PD) show clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective: To assess the frequency of dystonia-linked pathogenic variants in PD. Methods: We screened sequencing data from 15,738 individuals (7,851 PD, 4,287 atypical parkinsonism, and 3,600 unaffected) from GP2 and AMP-PD for variants in genes linked to isolated dystonia, dystonia-parkinsonism, and myoclonus-dystonia. Results: Pathogenic variants were only identified in PD patients. Forty-five PD individuals (0.57%) carried 26 distinct (likely) pathogenic variants in nine dystonia-linked genes, most frequently in GCH1 , followed by VPS16 . Conclusion: Though rare, pathogenic variants in dystonia-linked genes are present in clinically and pathologically diagnosed PD. Our results reinforce GCH1 as a PD-relevant gene with clinical implications, while variants identified in other genes are rare and of sometimes uncertain relation to the PD phenotype.
- Open Access
- 14 May 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (8) , 1604-1617
Interpretable Machine Learning for Cross‐Cohort Prediction of Motor Fluctuations in Parkinson's Disease
Background: Motor fluctuations are a common complication in later stages of Parkinson's disease (PD) and significantly affect patients' quality of life. Robustly identifying risk and protective factors for this complication across distinct cohorts could lead to improved disease management. Objectives: The goal was to identify key prognostic factors for motor fluctuations in PD by using machine learning and exploring their associations in the context of the prior literature. Methods: We applied interpretable machine learning techniques for time‐to‐event analysis and prediction of motor fluctuations within 4 years in three longitudinal PD cohorts. Prognostic models were cross‐validated to identify robust predictors, and the performance, stability, calibration, and utility for clinical decision‐making were assessed. Results: Cross‐validation analyses suggest the effectiveness of the models in identifying significant baseline predictors. Movement Disorder Society‐Unified Parkinson's Disease Rating Scale parts I and II, freezing of gait, axial symptoms, rigidity, and pathogenic GBA and LRRK2 variants were positively correlated with motor fluctuations. Conversely, motor fluctuations were inversely associated with tremors and late age of onset of PD. Cross‐cohort data integration provides more stable predictions, reducing cohort‐specific bias and enhancing robustness. Decision curve and calibration analysis confirms the models' practical utility and alignment of predictions with observed outcomes. Conclusions: Interpretable machine learning models can effectively predict motor fluctuations in PD from baseline clinical data. Cross‐cohort data integration increases the stability of selected predictors. Calibration and decision curve analyses confirm the model's reliability and utility for practical clinical applications. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 14 May 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (8) , 1604-1617
Open AccessInterpretable Machine Learning for Cross‐Cohort Prediction of Motor Fluctuations in Parkinson's Disease
Background: Motor fluctuations are a common complication in later stages of Parkinson's disease (PD) and significantly affect patients' quality of life. Robustly identifying risk and protective factors for this complication across distinct cohorts could lead to improved disease management. Objectives: The goal was to identify key prognostic factors for motor fluctuations in PD by using machine learning and exploring their associations in the context of the prior literature. Methods: We applied interpretable machine learning techniques for time‐to‐event analysis and prediction of motor fluctuations within 4 years in three longitudinal PD cohorts. Prognostic models were cross‐validated to identify robust predictors, and the performance, stability, calibration, and utility for clinical decision‐making were assessed. Results: Cross‐validation analyses suggest the effectiveness of the models in identifying significant baseline predictors. Movement Disorder Society‐Unified Parkinson's Disease Rating Scale parts I and II, freezing of gait, axial symptoms, rigidity, and pathogenic GBA and LRRK2 variants were positively correlated with motor fluctuations. Conversely, motor fluctuations were inversely associated with tremors and late age of onset of PD. Cross‐cohort data integration provides more stable predictions, reducing cohort‐specific bias and enhancing robustness. Decision curve and calibration analysis confirms the models' practical utility and alignment of predictions with observed outcomes. Conclusions: Interpretable machine learning models can effectively predict motor fluctuations in PD from baseline clinical data. Cross‐cohort data integration increases the stability of selected predictors. Calibration and decision curve analyses confirm the model's reliability and utility for practical clinical applications. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 3 May 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae187
Converging peripheral blood microRNA profiles in Parkinson's disease and progressive supranuclear palsy
MicroRNAs act via targeted suppression of messenger RNA translation in the DNA–RNA–protein axis. The dysregulation of microRNA(s) reflects the epigenetic changes affecting the cellular processes in multiple disorders. To understand the complex effect of dysregulated microRNAs linked to neurodegeneration, we performed a cross-sectional microRNA expression analysis in idiopathic Parkinson's disease (n = 367), progressive supranuclear palsy (n = 35) and healthy controls (n = 416) from the Luxembourg Parkinson's Study, followed by prediction modelling, enriched pathway analysis and target simulation of dysregulated microRNAs using probabilistic Boolean modelling. Forty-six microRNAs were identified to be dysregulated in Parkinson's disease versus controls and 16 in progressive supranuclear palsy versus controls with 4 overlapping significantly dysregulated microRNAs between the comparisons. Predictive power of microRNA subsets (including up to 100 microRNAs) was modest for differentiating Parkinson's disease or progressive supranuclear palsy from controls (maximal cross-validated area under the receiver operating characteristic curve 0.76 and 0.86, respectively) and low for progressive supranuclear palsy versus Parkinson's disease (maximal cross-validated area under the receiver operating characteristic curve 0.63). The enriched pathway analysis revealed natural killer cell pathway to be dysregulated in both, Parkinson's disease and progressive supranuclear palsy versus controls, indicating that the immune system might play an important role in both diseases. Probabilistic Boolean modelling of pathway dynamics affected by dysregulated microRNAs in Parkinson's disease and progressive supranuclear palsy revealed partially overlapping dysregulation in activity of the transcription factor EB, endoplasmic reticulum stress signalling, calcium signalling pathway, dopaminergic transcription and peroxisome proliferator-activated receptor gamma coactivator-1α activity, though involving different mechanisms. These findings indicated a partially convergent (sub)cellular end-point dysfunction at multiple levels in Parkinson's disease and progressive supranuclear palsy, but with distinctive underlying molecular mechanisms.
- 3 May 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae187
Open AccessConverging peripheral blood microRNA profiles in Parkinson's disease and progressive supranuclear palsy
MicroRNAs act via targeted suppression of messenger RNA translation in the DNA–RNA–protein axis. The dysregulation of microRNA(s) reflects the epigenetic changes affecting the cellular processes in multiple disorders. To understand the complex effect of dysregulated microRNAs linked to neurodegeneration, we performed a cross-sectional microRNA expression analysis in idiopathic Parkinson's disease (n = 367), progressive supranuclear palsy (n = 35) and healthy controls (n = 416) from the Luxembourg Parkinson's Study, followed by prediction modelling, enriched pathway analysis and target simulation of dysregulated microRNAs using probabilistic Boolean modelling. Forty-six microRNAs were identified to be dysregulated in Parkinson's disease versus controls and 16 in progressive supranuclear palsy versus controls with 4 overlapping significantly dysregulated microRNAs between the comparisons. Predictive power of microRNA subsets (including up to 100 microRNAs) was modest for differentiating Parkinson's disease or progressive supranuclear palsy from controls (maximal cross-validated area under the receiver operating characteristic curve 0.76 and 0.86, respectively) and low for progressive supranuclear palsy versus Parkinson's disease (maximal cross-validated area under the receiver operating characteristic curve 0.63). The enriched pathway analysis revealed natural killer cell pathway to be dysregulated in both, Parkinson's disease and progressive supranuclear palsy versus controls, indicating that the immune system might play an important role in both diseases. Probabilistic Boolean modelling of pathway dynamics affected by dysregulated microRNAs in Parkinson's disease and progressive supranuclear palsy revealed partially overlapping dysregulation in activity of the transcription factor EB, endoplasmic reticulum stress signalling, calcium signalling pathway, dopaminergic transcription and peroxisome proliferator-activated receptor gamma coactivator-1α activity, though involving different mechanisms. These findings indicated a partially convergent (sub)cellular end-point dysfunction at multiple levels in Parkinson's disease and progressive supranuclear palsy, but with distinctive underlying molecular mechanisms.
- Open Access
- 19 March 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-18
Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism
Parkinson’s disease (PD) is a highly heterogeneous disorder influenced by several environmental and genetic factors. Effective disease-modifying therapies and robust early-stage biomarkers are still lacking, and an improved understanding of the molecular changes in PD could help to reveal new diagnostic markers and pharmaceutical targets. Here, we report results from a cohort-wide blood plasma metabolic profiling of PD patients and controls in the Luxembourg Parkinson’s Study to detect disease-associated alterations at the level of systemic cellular process and network alterations. We identified statistically significant changes in both individual metabolite levels and global pathway activities in PD vs. controls and significant correlations with motor impairment scores. As a primary observation when investigating shared molecular sub-network alterations, we detect pronounced and coordinated increased metabolite abundances in xanthine metabolism in de novo patients, which are consistent with previous PD case/control transcriptomics data from an independent cohort in terms of known enzyme-metabolite network relationships. From the integrated metabolomics and transcriptomics network analysis, the enzyme hypoxanthine phosphoribosyltransferase 1 (HPRT1) is determined as a potential key regulator controlling the shared changes in xanthine metabolism and linking them to a mechanism that may contribute to pathological loss of cellular adenosine triphosphate (ATP) in PD. Overall, the investigations revealed significant PD-associated metabolome alterations, including pronounced changes in xanthine metabolism that are mechanistically congruent with alterations observed in independent transcriptomics data. The enzyme HPRT1 may merit further investigation as a main regulator of these network alterations and as a potential therapeutic target to address downstream molecular pathology in PD.
- 19 March 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-18
Open AccessComprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism
Parkinson’s disease (PD) is a highly heterogeneous disorder influenced by several environmental and genetic factors. Effective disease-modifying therapies and robust early-stage biomarkers are still lacking, and an improved understanding of the molecular changes in PD could help to reveal new diagnostic markers and pharmaceutical targets. Here, we report results from a cohort-wide blood plasma metabolic profiling of PD patients and controls in the Luxembourg Parkinson’s Study to detect disease-associated alterations at the level of systemic cellular process and network alterations. We identified statistically significant changes in both individual metabolite levels and global pathway activities in PD vs. controls and significant correlations with motor impairment scores. As a primary observation when investigating shared molecular sub-network alterations, we detect pronounced and coordinated increased metabolite abundances in xanthine metabolism in de novo patients, which are consistent with previous PD case/control transcriptomics data from an independent cohort in terms of known enzyme-metabolite network relationships. From the integrated metabolomics and transcriptomics network analysis, the enzyme hypoxanthine phosphoribosyltransferase 1 (HPRT1) is determined as a potential key regulator controlling the shared changes in xanthine metabolism and linking them to a mechanism that may contribute to pathological loss of cellular adenosine triphosphate (ATP) in PD. Overall, the investigations revealed significant PD-associated metabolome alterations, including pronounced changes in xanthine metabolism that are mechanistically congruent with alterations observed in independent transcriptomics data. The enzyme HPRT1 may merit further investigation as a main regulator of these network alterations and as a potential therapeutic target to address downstream molecular pathology in PD.
- Open Access
Polygenic risk scores validated in patient-derived cells stratify for mitochondrial subtypes of Parkinson’s disease
Background: Parkinson’s disease (PD) is the fastest growing neurodegenerative disorder, with affected individuals expected to double during the next 20 years. This raises the urgent need to better understand the genetic architecture and downstream cellular alterations underlying PD pathogenesis, in order to identify more focused therapeutic targets. While only ∼10% of PD cases can be clearly attributed to monogenic causes, there is mounting evidence that additional genetic factors could play a role in idiopathic PD (iPD). In particular, common variants with low to moderate effect size in multiple genes regulating key neuroprotective activities may act as risk factors for PD. In light of the well-established involvement of mitochondrial dysfunction in PD, we hypothesized that a fraction of iPD cases may harbour a pathogenic combination of common variants in nuclear-encoded mitochondrial genes, ultimately resulting in neurodegeneration. Methods: to capture this mitochondria-related “missing heritability”, we leveraged on existing data from previous genome-wide association studies (GWAS) – i.e., the large PD GWAS from Nalls and colleagues. We then used computational approaches based on mitochondria-specific polygenic risk scores (mitoPRSs) for imputing the genotype data obtained from different iPD case-control datasets worldwide, including the Luxembourg Parkinson’s Study (412 iPD patients and 576 healthy controls) and the COURAGE-PD cohorts (7270 iPD cases and 6819 healthy controls). Results: applying this approach to gene sets controlling mitochondrial pathways potentially relevant for neurodegeneration in PD, we demonstrated that common variants in genes regulating Oxidative Phosphorylation (OXPHOS -PRS ) were significantly associated with a higher PD risk both in the Luxembourg Parkinson’s Study (odds ratio, OR=1.31[1.14-1.50], p =5.4e-04) and in COURAGE-PD (OR=1.23[1.18-1.27], p =1.5e-29). Functional analyses in primary skin fibroblasts and in the corresponding induced pluripotent stem cells-derived neuronal progenitor cells from Luxembourg Parkinson’s Study iPD patients stratified according to the OXPHOS -PRS, revealed significant differences in mitochondrial respiration between high and low risk groups ( p < 0.05). Finally, we also demonstrated that iPD patients with high OXPHOS -PRS have a significantly earlier age at disease onset compared to low-risk patients. Conclusions: our findings suggest that OXPHOS-PRS may represent a promising strategy to stratify iPD patients into pathogenic subgroups – in which the underlying neurodegeneration is due to a genetically defined mitochondrial burden – potentially eligible for future, more tailored mitochondrially targeted treatments.
Open AccessPolygenic risk scores validated in patient-derived cells stratify for mitochondrial subtypes of Parkinson’s disease
Background: Parkinson’s disease (PD) is the fastest growing neurodegenerative disorder, with affected individuals expected to double during the next 20 years. This raises the urgent need to better understand the genetic architecture and downstream cellular alterations underlying PD pathogenesis, in order to identify more focused therapeutic targets. While only ∼10% of PD cases can be clearly attributed to monogenic causes, there is mounting evidence that additional genetic factors could play a role in idiopathic PD (iPD). In particular, common variants with low to moderate effect size in multiple genes regulating key neuroprotective activities may act as risk factors for PD. In light of the well-established involvement of mitochondrial dysfunction in PD, we hypothesized that a fraction of iPD cases may harbour a pathogenic combination of common variants in nuclear-encoded mitochondrial genes, ultimately resulting in neurodegeneration. Methods: to capture this mitochondria-related “missing heritability”, we leveraged on existing data from previous genome-wide association studies (GWAS) – i.e., the large PD GWAS from Nalls and colleagues. We then used computational approaches based on mitochondria-specific polygenic risk scores (mitoPRSs) for imputing the genotype data obtained from different iPD case-control datasets worldwide, including the Luxembourg Parkinson’s Study (412 iPD patients and 576 healthy controls) and the COURAGE-PD cohorts (7270 iPD cases and 6819 healthy controls). Results: applying this approach to gene sets controlling mitochondrial pathways potentially relevant for neurodegeneration in PD, we demonstrated that common variants in genes regulating Oxidative Phosphorylation (OXPHOS -PRS ) were significantly associated with a higher PD risk both in the Luxembourg Parkinson’s Study (odds ratio, OR=1.31[1.14-1.50], p =5.4e-04) and in COURAGE-PD (OR=1.23[1.18-1.27], p =1.5e-29). Functional analyses in primary skin fibroblasts and in the corresponding induced pluripotent stem cells-derived neuronal progenitor cells from Luxembourg Parkinson’s Study iPD patients stratified according to the OXPHOS -PRS, revealed significant differences in mitochondrial respiration between high and low risk groups ( p < 0.05). Finally, we also demonstrated that iPD patients with high OXPHOS -PRS have a significantly earlier age at disease onset compared to low-risk patients. Conclusions: our findings suggest that OXPHOS-PRS may represent a promising strategy to stratify iPD patients into pathogenic subgroups – in which the underlying neurodegeneration is due to a genetically defined mitochondrial burden – potentially eligible for future, more tailored mitochondrially targeted treatments.
- Open Access
Accurate long-read sequencing identified GBA variants as a major genetic risk factor in the Luxembourg Parkinson’s study
Heterozygous variants in the glucocerebrosidase GBA gene are an increasingly recognized risk factor for Parkinson’s disease (PD). Due to the pseudogene GBAP1 that shares 96% sequence homology with the GBA coding region, accurate variant calling by array-based or short-read sequencing methods remains a major challenge in understanding the genetic landscape of GBA -related PD. We established a novel long-read sequencing technology for assessing the full length of the GBA gene. We used subsequent regression models for genotype-phenotype analyses. We sequenced 752 patients with parkinsonism and 806 healthy controls of the Luxembourg Parkinson’s study. All GBA variants identified showed a 100% true positive rate by Sanger validation. We found 12% of unrelated PD patients carrying GBA variants. Three novel variants of unknown significance (VUS) were identified. Using a structure-based approach, we defined a potential risk prediction method for VUS. This study describes the full landscape of GBA -related parkinsonism in Luxembourg, showing a high prevalence of GBA variants as the major genetic risk for PD. Our approach provides an important advancement for highly accurate GBA variant calling, which is essential for providing access to emerging causative therapies for GBA carriers.
Open AccessAccurate long-read sequencing identified GBA variants as a major genetic risk factor in the Luxembourg Parkinson’s study
Heterozygous variants in the glucocerebrosidase GBA gene are an increasingly recognized risk factor for Parkinson’s disease (PD). Due to the pseudogene GBAP1 that shares 96% sequence homology with the GBA coding region, accurate variant calling by array-based or short-read sequencing methods remains a major challenge in understanding the genetic landscape of GBA -related PD. We established a novel long-read sequencing technology for assessing the full length of the GBA gene. We used subsequent regression models for genotype-phenotype analyses. We sequenced 752 patients with parkinsonism and 806 healthy controls of the Luxembourg Parkinson’s study. All GBA variants identified showed a 100% true positive rate by Sanger validation. We found 12% of unrelated PD patients carrying GBA variants. Three novel variants of unknown significance (VUS) were identified. Using a structure-based approach, we defined a potential risk prediction method for VUS. This study describes the full landscape of GBA -related parkinsonism in Luxembourg, showing a high prevalence of GBA variants as the major genetic risk for PD. Our approach provides an important advancement for highly accurate GBA variant calling, which is essential for providing access to emerging causative therapies for GBA carriers.
- Open Access
- 2 September 2022
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 8 (1) , 1
Publisher Correction: Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes
- 2 September 2022
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 8 (1) , 1
Open AccessPublisher Correction: Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes